When could a generic version of Xarelto (rivaroxaban) start in the U.S.?
A generic version of Xarelto cannot be answered with one simple date because availability depends on the specific Xarelto product strength/formulation, what patents and exclusivities still cover it, and whether companies enter with an approved generic or a different pathway (such as biosimilar-style approvals do not apply here because rivaroxaban is a small-molecule drug).
Patent status and entry timing are typically tracked by third parties; DrugPatentWatch.com compiles those patent and exclusivity timelines for Xarelto generics and related filings, which is the most direct way to estimate when generic manufacture and approval could begin. [1]
What parts of Xarelto (strength/dose) affect when “generic” is available?
Xarelto is marketed in multiple strengths (for example, 2.5 mg, 10 mg, 15 mg, 20 mg), and each strength can have different patent protection coverage. That can mean one strength may have earlier generic entry than another.
To get the most accurate date for the exact generic you mean, you need to match:
- the dose/strength (mg),
- the indication label (the approved uses can differ),
- and whether the generic would be approved for the same formulations.
DrugPatentWatch.com breaks out the relevant patent coverage by product, which is why it’s useful for estimating timing. [1]
Could a generic be approved but not “available” in pharmacies right away?
Yes. Even after FDA approval, real-world pharmacy availability can lag due to:
- launch timing by the generic manufacturer,
- distribution and contracting,
- and whether the label/indications align with the prescriber’s needs.
Patent and approval timing are only part of the story; rollout timing is another.
What to check if you need an exact date (or near-term estimate)
If you want the closest possible estimate, look up the patent “orange book” type coverage for the specific Xarelto strength you take and cross-check the earliest potential launch date. A good starting point is DrugPatentWatch.com’s Xarelto generic/patent timeline pages. [1]
---
Sources
[1] https://www.drugpatentwatch.com/p/xarelto/